Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Intranasal spray product candidates will target known and new respiratory viruses.
July 22, 2021
By: Tim Wright
Editor-in-Chief, Contract Pharma
Nanopharm Ltd., an Aptar Pharma company and provider of contract research and development of orally inhaled and nasally delivered drug products (OINDP), and Leyden Labs, a company targeting commonalities of viral families to protect humanity from known and future viruses, have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products. Leyden Labs’ platform targets commonalities of viral families to develop product candidates that protect against many strains of a virus simultaneously with a single product. Its easy-to-use nasal spray product candidates may allow people to immediately protect themselves against infection and transmission of known and new viruses, protecting humanity from the devastating effects of future pandemics and recurring seasonal outbreaks such as influenza and coronaviruses. Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies. Formulation approaches utilizing muco-adhesive technologies will be part of the development process to try to achieve maximum deposition and retention in the nasal cavity. In parallel, a powder system may also be assessed to provide long-term stability. “Leyden Labs is taking a really exciting approach to finding solutions for the broad-spectrum prophylactic protection against respiratory viruses,” said Jag Shur, CEO, Nanopharm. “Their platform and portfolio of product candidates show real promise, and we are proud to be a part of its development to fast-track its approach towards the clinic, utilizing our fundamental scientific understanding of OINDPs and our knowledge of how to expedite product development.” Guillaume Brouet, vice president analytical, regulatory and scientific affairs, Aptar Pharma, said, “We are pleased to support Leyden Labs in this important development, which reinforces the Aptar Pharma Services mission to further help customers during their entire drug development journey and deliver them a complete solution.” Koenraad Wiedhaup, CEO, Leyden Labs, said, “Nanopharm’s team has the world-leading expertise needed to understand and develop safe, effective formulations targeting respiratory viruses. This partnership enables us to efficiently bring our product candidates to people in need of better protection against new pandemics and seasonal outbreaks like those caused by influenza and coronaviruses. We look forward to continuing to work with Nanopharm in the future to further develop additional product candidates and swiftly advance them into the clinic.” All formulation development will be performed at Nanopharm’s facility in Newport, UK, which houses its R&D laboratories for formulation and characterization of inhaled and nasal products, supporting start-up biotech, big pharma or generic companies globally.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !